Lung cancer is the leading cause of death worldwide. Current treatment modalities,
including chemotherapy, radiotherapy and surgery, provide only limited improvement in the …

The Epidermal Growth Factor Receptor (EGFR) family, including EGFR, HER2, HER3, and
HER4, is implicated in the development and progression of cancer, and is expressed in …

In the last decade, important advances have been made in understanding of cancer biology,
particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of …

Although chemotherapy remains the standard of care for lung cancer, new less toxic drugs
are urgently needed. Targeted agents represent a new era in cancer therapy, and non …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

Introduction: EGFR is the receptor for epidermal growth factor (EGF) and belongs to the
protein tyrosine kinase (PTK) receptor. It is closely related to the inhibition of tumor cell …

In the last decade, better understanding of the role of epidermal growth factor receptor in the
pathogenesis and progression of non-small cell lung cancer has led to a revolution in the …

Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes
one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR …

Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major
forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers …

The identification of certain molecular mechanisms underlying lung carcinogenesis and
progression has led to the development of targeted agents against different families of …